Thomas Cavanaugh - 01 Sep 2026 Form 3 Insider Report for JOHNSON & JOHNSON (JNJ)

Reporting relationship
EVP WW Chair, Innovative Med.
Issuer ticker
JNJ
Reported as of
01 Sep 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
01 Sep 2026, 16:52:32 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joleen Morgan, as attorney-in-fact for Thomas Cavanaugh

Key filing fact

Thomas Cavanaugh filed Form 3 for JOHNSON & JOHNSON (JNJ) on 01 Sep 2026.

Key facts

  • This page summarizes Thomas Cavanaugh's Form 3 filing for JOHNSON & JOHNSON (JNJ).
  • 0 reported transactions and 10 derivative rows are listed below.
  • Accepted by SEC: 01 Sep 2026, 16:52.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002151011 Primary reporting owner

Cavanaugh Thomas

Relationship
EVP WW Chair, Innovative Med.
Address
ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK
Signature
/s/ Joleen Morgan, as attorney-in-fact for Thomas Cavanaugh
Signature date
01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JNJ holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
71
Date
01 Sep 2026
Ownership
Direct
JNJ holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
428
Date
01 Sep 2026
Ownership
By 401k
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,839
Exercise price
$243.45
Footnotes
F2
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
25,493
Exercise price
$156.15
Footnotes
F2
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,311
Exercise price
$157.92
Footnotes
F2
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,081
Exercise price
$162.75
Footnotes
F2
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,906
Exercise price
$165.89
Footnotes
F3
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,383
Exercise price
$164.62
Footnotes
F3
JNJ holding Derivative

Employee Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,543
Exercise price
$151.41
Footnotes
F3
JNJ holding Derivative

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,275
Exercise price
Footnotes
F4
JNJ holding Derivative

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,097
Exercise price
Footnotes
F5
JNJ holding Derivative

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
965
Exercise price
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2026).

Footnote F2

Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

Footnote F3

Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.

Footnote F4

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

Footnote F5

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

Footnote F6

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .